title: Postoperative alpha 2-adrenergic stimulation attenuates protein catabolism.
abstract: The metabolic effects of continuous intravenous (IV) application of the alpha 2 agonist clonidine were evaluated by assessment of nitrogen economy and postaggression endocrine patterns. Twenty-four patients undergoing abdominothoracic esophageal cancer resection were studied. Thirteen of these patients with alcohol abuse were treated postoperatively with IV clonidine for prevention of alcohol withdrawal syndrome. Eleven patients who were not treated with clonidine served as controls. All patients were treated in a standardized manner in regard to surgical technique, balanced anesthesia, and postoperative intensive care treatment, including thoracic epidural analgesia with bupivacaine and fentanyl. Isonitrogenous and isocaloric nutrition was comparable in all patients. A significantly improved cumulated 6-day nitrogen balance was found in clonidine-treated patients (-1.5 +/- 4.9 g nitrogen) compared to the control group (-17.6 +/- 4.2 g nitrogen) (P < 0.05). The main reason for improved nitrogen economy may be clonidine-induced growth hormone (GH) release. The pattern of insulin-like growth factor I (IGF-I) and insulin-like growth factor binding protein 3 (IGFBP-3) concentrations could support this hypothesis.
authors.affiliation: Department of Anesthesia and Intensive Care Medicine, University of Münster, Germany.
authors.forename: N
authors.initials: N
authors.lastname: Mertes
authors.forename: C
authors.initials: C
authors.lastname: Goeters
authors.forename: M
authors.initials: M
authors.lastname: Kuhmann
authors.forename: J F
authors.initials: JF
authors.lastname: Zander
mesh_terms: D000316:Adrenergic alpha-Agonists / Q000008:administration & dosage*; D000437:Alcoholism / Q000150:complications / Q000188:drug therapy / Q000378:metabolism; D001798:Blood Proteins / Q000032:analysis; D003000:Clonidine / Q000008:administration & dosage*; D004938:Esophageal Neoplasms / Q000150:complications / Q000378:metabolism / Q000601:surgery; D005934:Glucagon / Q000097:blood; D005947:Glucose / Q000008:administration & dosage; D006801:Humans; D007262:Infusions, Intravenous; D007328:Insulin / Q000097:blood; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000097:blood; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D008875:Middle Aged; D009584:Nitrogen / Q000652:urine; D010289:Parenteral Nutrition, Total; D011182:Postoperative Care; D011300:Preoperative Care; D011506:Proteins / Q000378:metabolism*; D013312:Stress, Physiological / Q000209:etiology / Q000378:metabolism; D013514:Surgical Procedures, Operative / Q000009:adverse effects; D014993:Xylitol / Q000008:administration & dosage
chemical_list: D000316:Adrenergic alpha-Agonists; D001798:Blood Proteins; D007328:Insulin; D018972:Insulin-Like Growth Factor Binding Protein 3; D011506:Proteins; D007334:Insulin-Like Growth Factor I; D005934:Glucagon; D005947:Glucose; D003000:Clonidine; D009584:Nitrogen; D014993:Xylitol